Grace Therapeutics (GRCE) Stock Overview
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GRCE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Grace Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.12 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$1.75 |
| Beta | 0.75 |
| 1 Month Change | 7.85% |
| 3 Month Change | 28.35% |
| 1 Year Change | 45.07% |
| 3 Year Change | 34.11% |
| 5 Year Change | -87.75% |
| Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth
Feb 19
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Sep 02We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
Apr 20Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Nov 14We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate
May 10Acasti Pharma GAAP EPS of -$0.10
Aug 11Shareholder Returns
| GRCE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.6% | 0.9% | 0.5% |
| 1Y | 45.1% | 25.0% | 15.5% |
Return vs Industry: GRCE exceeded the US Pharmaceuticals industry which returned 27.2% over the past year.
Return vs Market: GRCE exceeded the US Market which returned 13.9% over the past year.
Price Volatility
| GRCE volatility | |
|---|---|
| GRCE Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GRCE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GRCE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 6 | Prashant Kohli | www.gracetx.com |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN).
Grace Therapeutics, Inc. Fundamentals Summary
| GRCE fundamental statistics | |
|---|---|
| Market cap | US$62.21m |
| Earnings (TTM) | -US$5.98m |
| Revenue (TTM) | n/a |
Is GRCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRCE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.98m |
| Earnings | -US$5.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GRCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 17:29 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grace Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |